JP2010513552A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513552A5
JP2010513552A5 JP2009543061A JP2009543061A JP2010513552A5 JP 2010513552 A5 JP2010513552 A5 JP 2010513552A5 JP 2009543061 A JP2009543061 A JP 2009543061A JP 2009543061 A JP2009543061 A JP 2009543061A JP 2010513552 A5 JP2010513552 A5 JP 2010513552A5
Authority
JP
Japan
Prior art keywords
cancer
group
hydrogen
halo
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009543061A
Other languages
English (en)
Japanese (ja)
Other versions
JP5166441B2 (ja
JP2010513552A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/087044 external-priority patent/WO2008076704A1/en
Publication of JP2010513552A publication Critical patent/JP2010513552A/ja
Publication of JP2010513552A5 publication Critical patent/JP2010513552A5/ja
Application granted granted Critical
Publication of JP5166441B2 publication Critical patent/JP5166441B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009543061A 2006-12-21 2007-12-11 癌治療用イミダゾリジノニルアミノピリミジン化合物 Expired - Fee Related JP5166441B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87130206P 2006-12-21 2006-12-21
US60/871,302 2006-12-21
PCT/US2007/087044 WO2008076704A1 (en) 2006-12-21 2007-12-11 Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer

Publications (3)

Publication Number Publication Date
JP2010513552A JP2010513552A (ja) 2010-04-30
JP2010513552A5 true JP2010513552A5 (enExample) 2011-01-27
JP5166441B2 JP5166441B2 (ja) 2013-03-21

Family

ID=39186811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543061A Expired - Fee Related JP5166441B2 (ja) 2006-12-21 2007-12-11 癌治療用イミダゾリジノニルアミノピリミジン化合物

Country Status (14)

Country Link
US (1) US8101628B2 (enExample)
EP (1) EP2125793B1 (enExample)
JP (1) JP5166441B2 (enExample)
KR (1) KR101088291B1 (enExample)
CN (1) CN101563342B (enExample)
AT (1) ATE479680T1 (enExample)
AU (1) AU2007334039B2 (enExample)
BR (1) BRPI0721045A2 (enExample)
CA (1) CA2671738A1 (enExample)
DE (1) DE602007008952D1 (enExample)
EA (1) EA016177B1 (enExample)
ES (1) ES2349169T3 (enExample)
MX (1) MX2009006634A (enExample)
WO (1) WO2008076704A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016178B1 (ru) 2006-12-21 2012-02-28 Эли Лилли Энд Компани Соединения имидазолидинониламинопиримидина
EP2155735A2 (en) 2007-05-16 2010-02-24 Eli Lilly And Company Triazolyl aminopyrimidine compounds
TW200908981A (en) * 2007-05-16 2009-03-01 Lilly Co Eli Triazolyl aminopyrimidine compounds
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
WO2004063192A1 (en) * 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005012283A1 (en) * 2003-07-31 2005-02-10 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzothiophene compounds and uses thereof
CN101115749B (zh) * 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法
TW200800201A (en) * 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
EA016178B1 (ru) 2006-12-21 2012-02-28 Эли Лилли Энд Компани Соединения имидазолидинониламинопиримидина
EP2155735A2 (en) 2007-05-16 2010-02-24 Eli Lilly And Company Triazolyl aminopyrimidine compounds
TW200908981A (en) 2007-05-16 2009-03-01 Lilly Co Eli Triazolyl aminopyrimidine compounds

Similar Documents

Publication Publication Date Title
IL266563B (en) Heterocyclic compounds useful as pdk1 inhibitors
JP2010523670A5 (enExample)
JP2017095457A5 (enExample)
JP2009502743A5 (enExample)
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
EP4242236A3 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
JP2008044952A5 (enExample)
ME00937B (me) Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera
JP2011527666A5 (enExample)
JP2012082227A5 (enExample)
LT2197481T (lt) Rnr kompozicija, skirta nesmulkialąstelinio plaučių vėžio (nsclc) gydymui
MX2011008799A (es) Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
WO2013166004A3 (en) Organic compositions to treat kras-related diseases
JP2012509265A5 (enExample)
RU2011124894A (ru) Триазолотиадиазоловый ингибитор протеинкиназы с-мет
IL200764A (en) Preparations containing 3epha antibodies for use in the treatment of cancerous tumors
JP2010513552A5 (enExample)
JP2007510667A5 (enExample)
JP2017526662A5 (enExample)
JP2012509279A5 (enExample)
JP2012526766A5 (enExample)
NO20074360L (no) Behandling av metastaterte tumorer
CL2007000680A1 (es) Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc.
ZA200706919B (en) Pharmacogenomic markers for prognosis of solid tumors
JP2010513553A5 (enExample)